Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention
Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial | Journal of the American College of Cardiology
Figure S1: CHAMPION PHOENIX Study Design | Download Scientific Diagram
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention | JACC: Cardiovascular Interventions
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial - ScienceDirect
30570-9.fp.png "THE EFFICACY AND SAFETY OF CANGRELOR FOR PATIENTS UNDERGOING SINGLE VESSEL VERSUS MULTI VESSEL PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CHAMPION PHOENIX TRIAL | Journal of the American College of Cardiology")
THE EFFICACY AND SAFETY OF CANGRELOR FOR PATIENTS UNDERGOING SINGLE VESSEL VERSUS MULTI VESSEL PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CHAMPION PHOENIX TRIAL | Journal of the American College of Cardiology
PPT - CHAMPION PHOENIX PowerPoint Presentation, free download - ID:2257235
Subanalyses of the CHAMPION PHOENIX trial. | Download Scientific Diagram
CHAMPION-PHOENIX (IV Cangrelor vs Oral Clopidogrel for the Management of Periprocedural PCI Complications)
CHAMPION PHOENIX trial
CHAMPION PHOENIX IPST: Implications of Intraprocedural Stent Thrombosis During PCI from a Prospective, Randomized Trial of a Potent Intravenous ADP Antagonist vs. a Standard Ora... | tctmd.com
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute€Coronar
TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics – The CHAMPION PHOENIX Trial | tctmd.com
The Effect of Cangrelor and Access Site on Ischemic and Bleeding Events – Insights from CHAMPION PHOENIX J. Antonio Gutierrez, MD, MHS, Robert A. Harrington, - ppt download
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events | NEJM
Cangrelor Superior to Clopidogrel in CHAMPION PHOENIX Trial | DAIC
CHAMPION-PHOENIX (IV Cangrelor vs Oral Clopidogrel for the Management of Periprocedural PCI Complications)
CHAMPION PHOENIX: Effect of Cangrelor and Access Site on Ischemic and Bleeding Events | tctmd.com
Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention
Table 3 from Making Sense of Statistics in Clinical Trial Reports: Part 1 of a 4-Part Series on Statistics for Clinical Trials. | Semantic Scholar
Table 1 from Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention | Semantic Scholar
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events | NEJM
Figure1 | THE EFFICACY, SAFETY, AND NET CLINICAL BENEFIT OF CANGRELOR IN WOMEN UNDERGOING ELECTIVE OR URGENT PCI: INSIGHTS FROM THE CHAMPION-PHOENIX TRIAL | JACC: Journal of the American College of Cardiology
